Vivimed Labs CIRP: 6th CoC meet set for Aug 18, 2026

Latest disclosure: 6th CoC meeting on August 18

Vivimed Labs Ltd (BSE: 532660; NSE: VIVIMEDLAB) has intimated the exchange about a meeting of the Committee of Creditors (CoC) as part of its Corporate Insolvency Resolution Process (CIRP). The disclosure states that the 6th CoC meeting is scheduled for August 18, 2026. The update is significant for shareholders because CoC meetings are a key part of the insolvency process and typically cover process milestones, information sharing, and decisions required under the Insolvency and Bankruptcy Code, 2016.

The company’s exchange communication is framed as a CIRP-related compliance update to BSE. While the filing itself is brief, it places a clear date on the next formal creditor meeting. For a stock that is already trading at low absolute prices and is classified as small cap in the provided market snapshot, any insolvency process step tends to draw market attention.

What the CoC is and why this meeting matters

The Committee of Creditors is the primary decision-making body during CIRP, made up of the company’s financial creditors. In the normal course of the IBC process, the CoC meets periodically to review progress and consider actions presented by the insolvency professional. Each successive meeting number indicates the process is moving through scheduled checkpoints.

Vivimed Labs’ filing specifies this is the 6th CoC meeting, which implies multiple earlier meetings have already taken place since CIRP commenced. The agenda details are not provided in the text shared, but the date and meeting number establish that the formal creditor process is continuing.

CIRP status: Board powers suspended from April 15, 2026

A separate CIRP-related disclosure included in the provided text states that, pursuant to the commencement of CIRP under the Insolvency and Bankruptcy Code, 2016, the powers of the Board of Directors of Vivimed Labs Limited stand suspended with effect from April 15, 2026. This is a standard consequence of CIRP commencement, where management powers shift as per the insolvency framework.

The same text also references the “Board of Directors & IRP of the Company” and indicates that the board’s powers were suspended from the CIRP commencement date. The mention of IRP (interim resolution professional) signals that the insolvency process is being administered through the usual IBC architecture.

Stock and trading snapshot from the feed

The market data included alongside the disclosure shows Vivimed Labs’ share price around the ₹5 level on August 17, 2026. One line in the feed states the share price is ₹5 as on 17 August, 2026 at 16:29. Another portion states the stock stood at ₹4.91 at the close of the market, with a day high of ₹5.09 and a low of ₹4.85.

The same snapshot lists a market capitalisation of ₹41.13 crore. Separately, the feed also contains other price snapshots, including ₹4.86 as of August 13, 2026, and a different quote panel showing ₹6.55 (down 1.36%) and a FAQ line quoting ₹6.54. These are presented in the supplied text as-is, across different timestamps and panels.

Key facts mentioned in the disclosure and market panels

Board meeting and financial results timeline referenced

The feed also includes a board meeting intimation linked to financial reporting. Vivimed Labs’ Board of Directors was scheduled to convene on July 17, 2026 to review and approve audited financial results for the quarter and financial year ended March 31, 2026. The intimation states this would cover both standalone and consolidated results.

In addition, a compliance note in the provided text states that a board meeting to approve FY 2025-26 financial results, initially scheduled for May 30, 2026, was postponed, and that a new rescheduled date would be announced later. The market panel also lists board meeting entries, including May 30, 2026 (audited results) and July 17, 2026 (quarterly results), as shown in the “Corporate Actions” section.

Promoter pledge or encumbrance disclosure for FY26

Another disclosure referenced in the provided text says Vivimed Labs filed disclosures with BSE and NSE confirming that its promoters did not create any encumbrance on their shareholdings during the financial year ended March 31, 2026. This is typically tracked by investors because encumbrances can indicate financing against shares, although the text here only states that no such encumbrance was created during the stated period.

Shareholding pattern snapshot included in the feed

The text includes a table showing broad holdings for promoters and investors across quarters, ending March 2026. Promoter holding is shown declining versus March 2025, while “investors” are shown rising over the same period.

Market impact: what investors can infer from confirmed facts

From the confirmed items in the disclosure, the immediate market relevance is procedural: the CIRP is active, the board’s powers are stated to be suspended from April 15, 2026, and the next CoC meeting date is set for August 18, 2026. The price and market-cap snapshots included in the feed show the stock trading around ₹5 in one panel, with a cited close of ₹4.91 and a stated market capitalisation of ₹41.13 crore.

Beyond that, the feed shows multiple data points for the stock price from different timestamps and quote panels. Investors generally treat such panels as indicative, and rely on the official exchange price at the relevant timestamp for precise references.

Why the August 18 CoC date is a key marker

In an insolvency process, the cadence of CoC meetings is one of the few regular public indicators that the process is progressing through formal steps. Vivimed Labs’ intimation of the 6th meeting date provides a clear near-term milestone for stakeholders following the CIRP.

Separately, the presence of financial results-related board meeting intimations for FY ended March 31, 2026 in July 2026, along with a note about postponement of an earlier results meeting, suggests investors are also tracking corporate reporting events alongside insolvency updates.

Conclusion

Vivimed Labs’ latest exchange update puts the next CIRP milestone on the calendar, with the 6th CoC meeting scheduled for August 18, 2026. The company’s earlier disclosure states that board powers stand suspended from April 15, 2026, the date of CIRP commencement. The next confirmed step for the market to watch, based on the provided text, is the outcome and follow-up filings after the August 18 CoC meeting.